Abeona therapeutics granted second 180-day period by nasdaq to regain compliance with minimum bid price rule

New york and cleveland, may 19, 2022 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo), a fully-integrated leader in cell and gene therapy, today announced that the company has been granted an additional 180-day period from nasdaq's listing qualification department, through november 14, 2022, to regain compliance with the $1.00 minimum bid price requirement for continued listing on the nasdaq capital market. the company's common stock continues to trade on the nasdaq capital market under the symbol "abeo."
ABEO Ratings Summary
ABEO Quant Ranking